41147-81-3

Usage

Uses

Used in Pharmaceutical Research:
2-amino-1-(3-bromophenyl)ethan-1-ol is utilized in pharmaceutical research as a compound with potential therapeutic applications. Its ability to modulate neurotransmitter levels makes it a candidate for the development of treatments for various neurological and psychiatric disorders, such as depression, anxiety, and other mood-related conditions.
Used in Neuroscientific Studies:
In the field of neuroscientific research, 2-amino-1-(3-bromophenyl)ethan-1-ol serves as a valuable tool for studying the effects of psychoactive substances on the central nervous system. Its impact on neurotransmitter levels provides insights into the mechanisms of action of stimulants and entactogens, contributing to a better understanding of their potential benefits and risks.
Used in Recreational Settings:
Despite its potential therapeutic uses, 2-amino-1-(3-bromophenyl)ethan-1-ol has also been reported for recreational purposes due to its psychoactive effects. Its use in this context, however, is not recommended due to the potential for abuse and the lack of regulation and oversight in its production and distribution.

InChI:InChI=1/C8H10BrNO/c9-7-3-1-2-6(4-7)8(11)5-10/h1-4,8,11H,5,10H2

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 7677-24-9 trimethylsilyl cyanide 
• 943911-72-6 2-azido-1-(3-bromophenyl)ethanol 
• 39220-96-7 1-(3-bromophenyl)-2-nitroethanol 

Downstream Products

• 943910-36-9 5-(3-bromophenyl)oxazolidin-2-one 

Relevant academic research and scientific papers

NEW MACROCYCLIC LRRK2 KINASE INHIBITORS

Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.

Lewis acid mediated intramolecular C-O bond formation of alkanol-epoxide leading to substituted morpholine and 1,4-oxazepane derivatives: Total synthesis of (±)-Viloxazine

Substituted morpholines have been efficiently synthesised in good yields from nitrogen tethered alkanol-epoxide mediated by boron trifluoride etherate. The methodology has been used for the total synthesis of (±)-viloxazine.

NOVEL IMIDAZOLIDINE DERIVATIVES

The invention is concerned with novel imidazolidine derivatives of formula (I) wherein R1 to R3, A, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR al

Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase

A novel class of 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase is described. This report discusses the SAR of 4-(2-hydroxy-2-phenylethylamino)-substituted pyridones with improved IGF-1R potency.

OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of Formula (I): Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Discovery and optimisation of potent, selective, ethanolamine inhibitors of bacterial phenylalanyl tRNA synthetase

High throughput screening of Staphylococcus aureus phenylalanyl tRNA synthetase (FRS) identified ethanolamine 1 as a sub-micromolar hit. Optimisation studies led to the enantiospecific lead 64, a single-figure nanomolar inhibitor. The inhibitor series shows selectivity with respect to the mammalian enzyme and the potential for broad spectrum bacterial FRS inhibition.